What will happen to biomedical research and health care in the aftermath of the 2024 election? The differences in outcomes couldn’t be more stark.
The Supreme Court last week upended one of the underpinnings of administrative law by weakening the authority of federal health agencies to rely on technical expertise as they regulate medical products, issue coverage decisions, and respond to public health crises.
Source: White HouseIn a fiery State of the Union speech designed to showcase his performance as a veteran politician, President Joe Biden leaned into his accomplishments in health care.
It’s a divorce everyone has an opinion on.
When you are making a point that the country that put humans on the moon also has the capacity to cure cancers, venue and timing matter. On Sept. 12, President Joe Biden chose John F. Kennedy Presidential Library and Museum—and the 60th anniversary of Kennedy’s 1962 moonshot speech—to announce his plan’s latest iteration.
The Advanced Research Projects Agency for Health, the centerpiece of the Biden Administration’s war on disease, is designed to be something much more than an ordinary federal bureaucracy.
President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.”
Now that Joseph R. Biden Jr. is inaugurated and safely ensconced in the White House, cancer groups expect him to pick up where he left off as vice president four years ago—pursuing a sober and ambitious agenda for accelerating progress in cancer research.
On Nov. 15, shortly after midnight, President Donald J. Trump tweeted a link to a New York Post headline:
For the first time in U.S. history, the White House will soon be occupied by a president who has demonstrated a deep understanding of cancer research.
